We have constructed a term sheet to raise $1.5 million to support a Phase II clinical trial in COVID patients in local Alberta hospitals. We maintain the current $7.50...
On the eve of 2021 SolAeroMed received regulatory notification from Health Canada that our proposed clinical trial of S-1226 in COVID patients received official approval. This is approval was...
While most of SolAeroMed efforts are focused on advancing clinical trial development of our lead CO2/perflubron S-1226 drug, we have also made recent progress in our S-1229 Cyclodextrin drug...
